Next Article in Journal
Instructions for Authors 2008
Previous Article in Journal
Antimicrobial Activities of some Synthesized Pyridines, Oxazines and Thiazoles from 3-Aryl-1-(2-naphthyl)prop-2-en-1-ones
 
 
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Effects of Ethanol or Naltrexone after Ethanol Exposure on Plasma Levels of Hepatic Enzymes, Lipid Profile and Apolipoprotein in Rats

by
Silvânia M. M. VASCONCELOS
1,*,
Paula M. SOARES
1,
Natália M. LIMA
1,
Roberto F. PEREIRA
2,
Renata S. ALVES
2,
Maria Gorette R. QUEIROZ
2,
Danielle S. MACEDO
1,
Rivelilson M. FREITAS
1,
Francisca Cléa F. SOUSA
1,
Marta Maria F. FONTELES
1 and
Glauce S. Barros VIANA
1
1
Department of Physiology and Pharmacology, Federal University of Ceará, Rua Cel. Nunes de Melo 1127, 60430-270, Fortaleza, Ceará, Brazil
2
Department of Clinical and Toxicological Analyses, Federal University of Ceará, Rua Cel. Nunes de Melo 1127, 60430-270, Fortaleza, Ceará, Brazil
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2008, 76(2), 305-320; https://doi.org/10.3797/scipharm.0804-02
Submission received: 4 April 2008 / Accepted: 29 May 2008 / Published: 31 May 2008

Abstract

This work studied the effects of ethanol and naltrexone on plasma levels of hepatic enzymes, lipid profiles and apoprotein (APO-A1). Rats were treated daily with ethanol for 7 days and, after ethanol discontinuation, they received naltrexone up to the 14th day. The results showed increased alanine aminotransferase (ALT) and aspartate aminotranferase (AST) activities, as well as total cholesterol (TC), triglycerides (TGI) and high density lipoprotein cholesterol (HDL-C) levels after ethanol. Naltrexone alone significantly increased APO-A1 and TGI levels and significantly decreased TC concentrations. Naltrexone treatment after ethanol exposure leads to a significant increase in both ALT (48%) and AST (34%). While no changes were seen in HDL-C levels, naltrexone blocked the increase in TC levels induced by ethanol. However, TGI as well as APO-A1 levels were maintained at higher values as compared to controls and similar to those observed to the naltrexone group without ethanol treatment. The work indicates that the hypolipaemic effect of naltrexone after ethanol exposure is a favorable point to the use of this opioid antagonist in the treatment of alcoholism.
Keywords: Ethanol; Naltrexone; Hepatic enzymes; Lipid profile; Apoproteins Ethanol; Naltrexone; Hepatic enzymes; Lipid profile; Apoproteins

Share and Cite

MDPI and ACS Style

VASCONCELOS, S.M.M.; SOARES, P.M.; LIMA, N.M.; PEREIRA, R.F.; ALVES, R.S.; QUEIROZ, M.G.R.; MACEDO, D.S.; FREITAS, R.M.; SOUSA, F.C.F.; FONTELES, M.M.F.; et al. Effects of Ethanol or Naltrexone after Ethanol Exposure on Plasma Levels of Hepatic Enzymes, Lipid Profile and Apolipoprotein in Rats. Sci. Pharm. 2008, 76, 305-320. https://doi.org/10.3797/scipharm.0804-02

AMA Style

VASCONCELOS SMM, SOARES PM, LIMA NM, PEREIRA RF, ALVES RS, QUEIROZ MGR, MACEDO DS, FREITAS RM, SOUSA FCF, FONTELES MMF, et al. Effects of Ethanol or Naltrexone after Ethanol Exposure on Plasma Levels of Hepatic Enzymes, Lipid Profile and Apolipoprotein in Rats. Scientia Pharmaceutica. 2008; 76(2):305-320. https://doi.org/10.3797/scipharm.0804-02

Chicago/Turabian Style

VASCONCELOS, Silvânia M. M., Paula M. SOARES, Natália M. LIMA, Roberto F. PEREIRA, Renata S. ALVES, Maria Gorette R. QUEIROZ, Danielle S. MACEDO, Rivelilson M. FREITAS, Francisca Cléa F. SOUSA, Marta Maria F. FONTELES, and et al. 2008. "Effects of Ethanol or Naltrexone after Ethanol Exposure on Plasma Levels of Hepatic Enzymes, Lipid Profile and Apolipoprotein in Rats" Scientia Pharmaceutica 76, no. 2: 305-320. https://doi.org/10.3797/scipharm.0804-02

Article Metrics

Back to TopTop